CoChat
Sign Up
Cited by 421Schizophrenia research and treatmentPharmacology and Obesity TreatmentParkinson's Disease Mechanisms and Treatments

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

Open access
Koro, Carol E, Fedder, Donald O, L'Italien, Gilbert J, Weiss, SheilaS, Magder, LaurenceS, Kreyenbuhl, Julie, Revicki, DennisA, Buchanan, RobertW·2002·BMJ
DOI 10.1136/bmj.325.7358.243PMC PMC117636
Open this paper in CoChat — free accountOpen PDF

Abstract

Objective : To quantify the association between olanzapine and diabetes. Design : Population based nested case-control study. Setting : United Kingdom based General Practice Research Database comprising 3.5 million patients followed between 1987 and 2000. Participants : 19 637 patients who had been diagnosed as having and treated for schizophrenia. 451 incident cases of diabetes were matched with 2696 controls. Main outcome measures : Diagnosis and treatment of diabetes. Results : Patients taking olanzapine had a significantly increased risk of developing diabetes than non-users of antipsychotics (odds ratio 5.8, 95% confidence interval 2.0 to 16.7) and those taking conventional antipsychotics (4.2, 1.5 to 12.2). Patients taking risperidone had a non-significant increased risk of developing diabetes than non-users of antipsychotics (2.2, 0.9 to 5.2) and those taking conventional antipsychotics (1.6, 0.7 to 3.8). Conclusion : Olanzapine is associated with a clinically important and significant increased risk of diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.325.7358.243

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 2

  1. Caro, 2000, Atypical antipsychotics and the risk of developing diabetes. International Society for Pharmacoeconomics and Outcomes Research European meeting, Belgium, 2000., Value Health, 3, MH2
  2. 10.1176/appi.ajp.124.7.978 · DOI

Cited by

Sorted by citations

Items 301–400 of 420

Related

See all

Metadata

Authors
Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L., Kreyenbuhl, J., Revicki, D., & Buchanan, R.
Affiliations
University of Maryland, Baltimore (US)
Corresponding author
Koro, Carol E
ORCID
Kreyenbuhl, Julie
Venue
BMJ
Publisher
BMJ
Published
2002-08-03
Volume
325
Issue
7358
Pages
243
ISSN
  • 0007-1447 (ISSN-L)
  • 0959-8138
  • 1468-5833
DOI
10.1136/bmj.325.7358.243
PMC
PMC117636
OpenAlex
W2160802754
Cited by
421
References
30
Citations by year
2026: 3 · 2025: 6 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 3 · 2018: 7 · 2017: 8 · 2016: 8 · 2015: 8 · 2014: 5 · 2013: 10 · 2012: 9
FWCI
37.10
Type
journal article
Language
en
Open access
Licence
www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
Locations
  • BMJ (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
olanzapine, risperidone, schizophrenia, diabetes risk, antipsychotic drugs, adverse drug reactions, typical antipsychotics, type 2 diabetes
MeSH terms
Olanzapine, Adult, Aged, Benzodiazepines, Diabetes Mellitus, Female, Follow-Up Studies, Humans, Male, Middle Aged, Pirenzepine, Regression Analysis, Risk Factors, Schizophrenia, Antipsychotic Agents, Cohort Studies, Odds Ratio, Case-Control Studies, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review